Date: 2017-11-09
Type of information: Nomination
Compound: supervisory board
Company: apceth (Germany)
Therapeutic area: Technology - Services
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 9, 2017, apceth Biopharma GmbH, a leading company developing the next generation of cell-based therapies, announced the appointment of a new Supervisory
Board. The Supervisory Board will be responsible for advising and supporting the company on its corporate and business strategies. The Board is composed of highly experienced members with successful track records in the pharma and biotech industry.
- Manfred Ruediger, Chairman, is a seasoned senior executive with over 20 years’ experience in leading biotech companies both at the management and board levels. He also has an extensive knowledge in advancing cell-based therapies towards late-stage clinical development and pre-commercialization stages.
- Hans-Jochem Kolb is a world renowned expert in the field of hematological oncology and a pioneer in cellular immunotherapy and bone marrow/stem cell transplantation. He performed the first successful bone marrow transplantation in Germany and is active as a consultant for various universities and biotech companies.
- Matthias Kromayer is a member of the Executive Board of MIG Verwaltungs AG which is responsible for the MIG Funds’ life sciences holdings. He has a comprehensive background
in strategic consulting and has advised more than 30 companies on their corporate strategy.
- Klaus Schollmeier has more than 30 years’ experience as a senior executive and advisor in the biotech industry as well as in investment banking. He serves as board member of
several European biotech companies.
Financial terms:
Latest news:
Is general: Yes
